Research Analysts Offer Predictions for AGIO Q3 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a note issued to investors on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.80) for the quarter, down from their prior forecast of ($1.79). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($4.87) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.79) EPS, FY2025 earnings at ($6.99) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.57) EPS, Q3 2026 earnings at ($1.52) EPS and FY2026 earnings at ($5.95) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. During the same period in the prior year, the business earned ($1.51) EPS. The company’s revenue for the quarter was up 28.4% on a year-over-year basis.

Several other research firms have also recently commented on AGIO. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Raymond James reaffirmed an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $52.00.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $45.09 on Friday. The business has a 50 day simple moving average of $44.64 and a 200 day simple moving average of $41.58. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $53.28. The stock has a market capitalization of $2.56 billion, a P/E ratio of -7.13 and a beta of 0.75.

Insider Activity at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Nordea Investment Management AB lifted its holdings in Agios Pharmaceuticals by 13.0% during the first quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock worth $7,824,000 after acquiring an additional 30,764 shares during the period. Caxton Associates LP bought a new stake in Agios Pharmaceuticals during the first quarter worth $1,087,000. Vanguard Group Inc. lifted its holdings in Agios Pharmaceuticals by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock worth $123,096,000 after acquiring an additional 59,851 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in Agios Pharmaceuticals by 87.3% during the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after acquiring an additional 316,100 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Agios Pharmaceuticals by 23.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after acquiring an additional 388,381 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.